Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy

Purpose: To report a case of neurotrophic keratopathy (NK) in a patient affected by primary congenital glaucoma (PCG) who undergone glaucoma drainage implant surgery. NK was successfully treated with human recombinant Nerve Growth Factor (Cenegermin) eye drops. Case report description: A 46-years-old patient affected by primary congenital glaucoma underwent Ahmed glaucoma valve implantation in the right eye, after several unsuccessful surgeries to control intraocular pressure (IOP) since the age of three. Surgical intervention was performed without complications, and IOP was well-controlled post-operatively. However, 1 month after surgery, he developed NK with stromal ulceration, initially treated with a topical combination of preservative-free artificial tears and antibiotic ointment. As NK did not resolve, a new treatment with Cenegermin 20 µg/ml eye drops, 6 times daily, was started. Outcome: NK completely resolved after 8 weeks of Cenegermin treatment, with complete restoration of corneal integrity and improvement of corneal sensitivity and transparency. Visual acuity in the operated eye reverted to the pre-operative value. Conclusion: Cenegermin was extremely effective in restoring corneal integrity in this PCG patient with NK.

Download Full-text

Pediatric Use of Recombinant Human Nerve Growth Factor 20 μg/mL Eye Drops (Cenegermin) for Bilateral Neurotrophic Keratopathy in Congenital Corneal Anesthesia

Cornea ◽

10.1097/ico.0000000000002612 ◽

2020 ◽

Vol 40 (2) ◽

pp. 228-231

Author(s):

Marco G. Leto ◽

Maria E. Toro ◽

Patricia E. Indemini ◽

Claudia Fruttero ◽

Marco Denina ◽

...

Keyword(s):

Nerve Growth Factor ◽

Growth Factor ◽

Eye Drops ◽

Nerve Growth ◽

Pediatric Use ◽

Human Nerve ◽

Neurotrophic Keratopathy ◽

Factor 20

Download Full-text

Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma

Proceedings of the National Academy of Sciences ◽

10.1073/pnas.0906678106 ◽

2009 ◽

Vol 106 (32) ◽

pp. 13469-13474 ◽

Cited By ~ 123

Author(s):

A. Lambiase ◽

L. Aloe ◽

M. Centofanti ◽

V. Parisi ◽

F. Mantelli ◽

...

Keyword(s):

Nerve Growth Factor ◽

Growth Factor ◽

Clinical Evidence ◽

Eye Drops ◽

Nerve Growth

Download Full-text

Topical Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy Caused by Wallenberg Syndrome

Cornea ◽

10.1097/ico.0000000000002928 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Erika Mandarà ◽

Daniele Brocca ◽

Francesco Pellegrini ◽

Emanuela Interlandi

Keyword(s):

Nerve Growth Factor ◽

Growth Factor ◽

Nerve Growth ◽

Wallenberg Syndrome ◽

Neurotrophic Keratopathy

Download Full-text

Nerve growth factor eye drops to treat glaucoma

Drug News & Perspectives ◽

10.1358/dnp.2010.23.6.1472299 ◽

2010 ◽

Vol 23 (6) ◽

pp. 361 ◽

Cited By ~ 11

Author(s):

A. Lambiase ◽

F. Mantelli ◽

S. Bonini

Keyword(s):

Nerve Growth Factor ◽

Growth Factor ◽

Eye Drops ◽

Nerve Growth

Download Full-text

Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study

British Journal of Ophthalmology ◽

10.1136/bjophthalmol-2018-312470 ◽

2019 ◽

pp. bjophthalmol-2018-312470 ◽

Cited By ~ 5

Author(s):

Marta Sacchetti ◽

Alessandro Lambiase ◽

Doreen Schmidl ◽

Leopold Schmetterer ◽

Mauro Ferrari ◽

...

Keyword(s):

Nerve Growth Factor ◽

Growth Factor ◽

Dry Eye ◽

Ocular Surface ◽

Multiple Dose ◽

Eye Drops ◽

Open Label ◽

Nerve Growth ◽

Link Type ◽

Human Nerve

BackgroundDry eye disease (DED) affects more than 14% of the elderly population causing decrease of quality of life, high costs and vision impairment. Current treatments for DED aim at lubricating and controlling inflammation of the ocular surface. Development of novel therapies targeting different pathogenic mechanisms is sought-after. The aim of this study is to evaluate safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops in patients with DED.MethodsForty consecutive patients with moderate to severe DED were included in a phase IIa, prospective, open label, multiple-dose, clinical trial to receive rhNGF eye drops at 20 µg/mL (Group 1: G1) or at 4 µg/mL (Group 2: G2) concentrations, two times a day in both eyes for 28 days (NCT02101281). The primary outcomes measures were treatment-emerged adverse events (AE), Symptoms Assessment in Dry Eye (SANDE) scale, ocular surface staining and Schirmer test.ResultsOf 40 included patients, 39 completed the trial. Both tested rhNGF eye drop concentrations were safe and well tolerated. Twenty-nine patients experienced at least one AE (14 in G1 and 15 in G2), of which 11 had at least 1 related AE (8 in G1 and 3 in G2). Both frequency and severity of DED symptoms and ocular surface damage showed significant improvement in both groups, while tear function improved only in G1.ConclusionsThe data of this study indicate that rhNGF eye drops in both doses is safe and effective in improving symptoms and signs of DED. Randomised clinical trials are ongoing to confirm the therapeutic benefit of rhNGF in DED.Trial registration numberNCT02101281.

Download Full-text

In Vivo Evaluation of Corneal Nerves and Epithelial Healing After Treatment With Recombinant Nerve Growth Factor for Neurotrophic Keratopathy

American Journal of Ophthalmology ◽

10.1016/j.ajo.2020.04.036 ◽

2020 ◽

Vol 217 ◽

pp. 278-286 ◽

Cited By ~ 3

Author(s):

Leonardo Mastropasqua ◽

Manuela Lanzini ◽

Harminder Sing Dua ◽

Alessandro D' Uffizi ◽

Marta Di Nicola ◽

...

Keyword(s):

Nerve Growth Factor ◽

Growth Factor ◽

In Vivo Evaluation ◽

Nerve Growth ◽

Corneal Nerves ◽

Neurotrophic Keratopathy ◽

Epithelial Healing

Download Full-text

Local anaesthesia decreases nerve growth factor induced masseter hyperalgesia

Scientific Reports ◽

10.1038/s41598-020-71620-8 ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Yuri M. Costa ◽

Fernando G. Exposto ◽

Eduardo E. Castrillon ◽

Paulo César R. Conti ◽

Leonardo R. Bonjardim ◽

...

Keyword(s):

Nerve Growth Factor ◽

Growth Factor ◽

Local Anaesthesia ◽

Isotonic Saline ◽

Local Anaesthetics ◽

Relevant Information ◽

Mechanical Sensitivity ◽

Lidocaine Group ◽

Nerve Growth ◽

The Right

Abstract The aim of this investigation was to evaluate the effects of local anaesthesia on nerve growth factor (NGF) induced masseter hyperalgesia. Healthy participants randomly received an injection into the right masseter muscle of either isotonic saline (IS) given as a single injection (n = 15) or an injection of NGF (n = 30) followed by a second injection of lidocaine (NGF + lidocaine; n = 15) or IS (NGF + IS; n = 15) in the same muscle 48 h later. Mechanical sensitivity scores of the right and left masseter, referred sensations and jaw pain intensity and jaw function were assessed at baseline, 48 h after the first injection, 5 min after the second injection and 72 h after the first injection. NGF caused significant jaw pain evoked by chewing at 48 and 72 h after the first injection when compared to the IS group, but without significant differences between the NGF + lidocaine and NGF + IS groups. However, the mechanical sensitivity of the right masseter 5 min after the second injection in the NGF + lidocaine group was significantly lower than the second injection in the NGF + IS and was similar to the IS group. There were no significant differences for the referred sensations. Local anaesthetics may provide relevant information regarding the contribution of peripheral mechanisms in the maintenance of persistent musculoskeletal pain.

Download Full-text